1 / 7

KYNAPID ™ (vernakalant hydrochloride injection) Cardiovascular and Renal Drugs Advisory Committee

KYNAPID ™ (vernakalant hydrochloride injection) Cardiovascular and Renal Drugs Advisory Committee. Astellas Pharma US, Inc. December 11, 2007. Introduction. Donald Raineri, Pharm.D. Senior Director, Regulatory Affairs Astellas Pharma US, Inc.

kendall
Download Presentation

KYNAPID ™ (vernakalant hydrochloride injection) Cardiovascular and Renal Drugs Advisory Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. KYNAPID™(vernakalant hydrochloride injection)Cardiovascular and Renal DrugsAdvisory Committee Astellas Pharma US, Inc. December 11, 2007

  2. Introduction Donald Raineri, Pharm.D. Senior Director, Regulatory AffairsAstellas Pharma US, Inc.

  3. Proposed Indication:Vernakalant injectionis indicated for the rapid conversion of atrial fibrillation of ≤ 7 days duration to sinus rhythm. Dosage and Administration: The initial infusion of vernakalant injection is 3 mg/kg infused over 10 minutes. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10-minute infusion of 2 mg/kg may be administered. Vernakalant Injection

  4. Key Attributes ofVernakalant Injection • Effective and rapid conversion of AF to sinus rhythm with reduction of AF symptoms • Durability of sinus rhythm out to 24 hours • Concomitant use with rate or rhythm control medications without affecting safety or efficacy • Well-characterized safety profile • Favorable risk-benefit profile • An important treatment alternative for patients with symptomatic atrial fibrillation

  5. Today’s Agenda

  6. Expert Consultants • David Fedida, M.D., Ph.D. Professor and Associate Head, Anesthesiology, Pharmacology and Therapeutics – University of British Columbia • Peter R. Kowey, M.D. President of the Main Line Health Heart Center William Wikoff Smith Chair in Cardiovascular Research Professor of Medicine and Clinical Pharmacology Jefferson Medical College • Craig Pratt, M.D. Director, Coronary Intensive Care Unit The Methodist DeBakey Heart Center, The Methodist Hospital • Edward L.C. Pritchett, M.D. Consulting Professor of Medicine Duke University Medical Center • Jeremy N. Ruskin, M.D. Director, Cardiac Arrhythmia Services Massachusetts General Hospital

  7. Astellas and Cardiome Experts Astellas Representatives: Marlowe Schneidkraut, Ph.D., DABTAssociate Director, Toxicology Jeen Liu, Ph.D.Director, Clinical Statistics Cardiome Representative: Garth Dickinson, M.D., FRCPCMedical Consultant Brian Mangal, MScDirector of Biostatistics

More Related